EUVIMEDEUVIMED entdecken
Crossref

Eligibility criteria for cancer drug trials in adult patients: Evidence from China, 2013–2021

Zhuo Ma, Yichen Zhang, Dingyi Chen, Mengyuan Fu, Kexin Han, Yi Zhang, Joseph S Ross, Luwen Shi, Zhuoling An, Xiaodong Guan iD

Cancer · 01.05.2026 · 132 (9)

DOI: 10.1002/cncr.70425 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 27.04.2026. Verfasst von Zhuo Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Antineoplastic Agents, Neoplasms, Patient Selection. Die Arbeit nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Eligibility criteria used in cancer clinical trials ensure internal validity but may restrict enrollment and limit external generalizability. The US National Cancer Institute (NCI) has recommended broader criteria, but similar guidance is lacking in China.

Methods

The authors reviewed cancer clinical trials registered on China’s National Medical Products Administration (NMPA) Registration and Information Disclosure Platform between 2013 and 2021. Eligibility criteria were classified as compliant or restrictive based on the US NCI recommendations. Trends over time and associations between trial characteristics and noncompliance were analyzed.

Results

There were 2448 cancer clinical trials investigating anticancer drugs registered in China. Eligibility criteria for performance status (PS), organ function, and comorbidities were used in 96.3%, 74.7%, and 95.3% of trials, respectively; overall, 97.0% used at least one restrictive criterion beyond NCI’s recommendations. The median number of restrictive criteria used was two (interquartile range [IQR], 1–3) for trials approved in 2013–2015, three (IQR, 2–4) for trials approved in 2016–2018, and three (IQR, 2–4) for trials approved in 2019–2021 ( p < .001). Noncompliance became more frequent for PS ( p = .000), cardiac function ( p = .005), and prior/concurrent malignancies ( p = .018) over time.

Conclusions

These findings highlight a need for more inclusive and modernized eligibility criteria for the advancement of cancer clinical trials in China.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicAntineoplastic AgentsNeoplasmsPatient SelectionEligibility DeterminationHumansChinaAdultUnited StatesFemaleNational Cancer Institute (U.S.)

Stichwörter der Autor:innen

Chinacancerclinical trialseligibility criteria

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.
  • Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • International Research Centre for Medicinal Administration, Peking University, Beijing, China.
  • Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Department of Health Policy and Management, Yale School of Public Health, and Center for Outcomes Research and Evaluation, Yale-New Haven Health System, New Haven, Connecticut, USA.

ORCID-Profile: Xiaodong Guan

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ma, Z., Zhang, Y., Chen, D., Fu, M., Han, K., Zhang, Y., Ross, J. S., Shi, L., An, Z., & Guan, X. (2026). Eligibility criteria for cancer drug trials in adult patients: Evidence from China, 2013–2021. Cancer, 132(9). https://doi.org/10.1002/cncr.70425

Vancouver

Ma Z, Zhang Y, Chen D, Fu M, Han K, Zhang Y, et al. Eligibility criteria for cancer drug trials in adult patients: Evidence from China, 2013–2021. Cancer. 2026;132(9). doi:10.1002/cncr.70425

BibTeX
@article{Ma2026,
  author = {Ma, Zhuo and Zhang, Yichen and Chen, Dingyi and Fu, Mengyuan and Han, Kexin and Zhang, Yi and Ross, Joseph S and Shi, Luwen and An, Zhuoling and Guan, Xiaodong},
  title = {Eligibility criteria for cancer drug trials in adult patients: Evidence from China, 2013–2021},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {9},
  doi = {10.1002/cncr.70425}
}
Kostenlos starten →